ESMO 2024 preview – Summit and BioNTech battle again
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
No shortcuts for Agenus
The FDA throws out the company’s second attempt at an accelerated approval.
Endometrial cancer becomes a three-horse race
Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.
We haven't lost focus, BioNTech insists
The company defends its cancer strategy, and says it's not a me-too developer.
